{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:56:06Z","timestamp":1792727766670,"version":"4.5.0"},"reference-count":110,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Anal cancer is a rare cancer that accounts for about 2% of all gastrointestinal tract malignancies. Among anal cancer, squamous cell cancer is the most common malignancy. The incidence of all stages of anal squamous cell cancer has been increasing. Human papillomavirus infection and immunosuppression are major risk factors for anal cancer. The management of anal cancer has evolved over the past several decades and continues to do so. Chemoradiation therapy remains the mainstay for treatment for most patients with early-stage disease, whereas systemic therapy is the primary treatment for patients with metastatic disease. Patients with persistent disease or recurrence following chemoradiation therapy are treated with salvage surgery. Access to novel cytotoxic combinations and immunotherapy has improved the outcomes of patients with advanced disease. This review provides an overview of advances in the management of anal cancer over the past two decades. This paper reviews the epidemiology, risk factors, pathology, diagnosis, and management of localized and advanced anal squamous cell cancer, highlights current knowledge gaps in the management of anal cancer, and discusses future directions.<\/jats:p>","DOI":"10.3390\/curroncol30030246","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T07:28:15Z","timestamp":1678692495000},"page":"3232-3250","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Anal Cancer: The Past, Present and Future"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0993-5553","authenticated-orcid":false,"given":"Talha Ashraf","family":"Gondal","sequence":"first","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noman","family":"Chaudhary","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, St. Klimints Orhidisky School of Medicine, Sofia, Bulgaria, College of Kinesiology, University of Saskatchewan, Saskatoon, SK S7N5B2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3124-2928","authenticated-orcid":false,"given":"Husnaat","family":"Bajwa","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aribah","family":"Rauf","sequence":"additional","affiliation":[{"name":"College of Kinesiology, University of Saskatchewan, Saskatoon, SK S7N5B2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duc","family":"Le","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada"},{"name":"Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2099-698X","authenticated-orcid":false,"given":"Shahid","family":"Ahmed","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada"},{"name":"Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"ref_1","unstructured":"National Cancer Institute: Surveillance, Epidemiology, and End Results Program (2023, March 10). Cancer Stat Facts: Anal Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/anus.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.soc.2016.07.013","article-title":"Pathology of anal cancer","volume":"26","author":"Hoff","year":"2017","journal-title":"Surg. Oncol. Clin. North Am."},{"key":"ref_3","first-page":"924","article-title":"International trends in anal cancer incidence rates","volume":"46","author":"Islami","year":"2017","journal-title":"Int. J. Epidemiol."},{"key":"ref_4","unstructured":"(2023, March 05). American Cancer Society: Cancer Facts and Figures 2023. American Cancer Society, 2023. Available online: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2023\/2023-cancer-facts-and-figures.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kang, Y.J., Smith, M., and Canfell, K. (2018). Anal cancer in high-income countries: Increasing burden of disease. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0205105"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1200\/JCO.2012.45.2524","article-title":"Changing patterns of anal canal carcinoma in the United States","volume":"31","author":"Nelson","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1473-3099(17)30653-9","article-title":"Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: A systematic review and meta-analysis","volume":"18","author":"Lin","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1016\/S2352-3018(19)30434-5","article-title":"Association of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: A systematic review and meta-analysis","volume":"7","author":"Kelly","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1470-2045(12)70080-3","article-title":"Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: A systematic review and meta-analysis","volume":"13","author":"Machalek","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41416-018-0273-9","article-title":"Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis","volume":"120","author":"Gilbert","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1111\/ajt.15942","article-title":"Burden of anal squamous cell carcinoma, squamous intraepithelial lesions and HPV16 infection in solid organ transplant recipients: A systematic review and meta-analysis","volume":"20","author":"Albuquerque","year":"2020","journal-title":"Am. J. Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosupressed transplant recipients: A meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1473-3099(19)30164-1","article-title":"Cervical determinants of anal HPV infection and high-grade anal lesions in women: A collaborative pooled analysis","volume":"19","author":"Lin","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ijc.33185","article-title":"A meta-analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale","volume":"148","author":"Clifford","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/91.8.708","article-title":"Tobacco smoking as a risk factor in anal carcinoma: An antiestrogenic mechanism?","volume":"91","author":"Frisch","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/jnci\/djz219","article-title":"Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States, 2001\u20132015","volume":"112","author":"Deshmukh","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/17474124.2020.1775583","article-title":"A 2020 update of anal cancer: The increasing problem in women and expanding treatment landscape","volume":"14","author":"Lum","year":"2020","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/bjc.2015.89","article-title":"Lifestyle and reproductive risk factors associated with anal cancer in women aged over 50 years","volume":"112","author":"Coffey","year":"2015","journal-title":"Br. J. Cancer."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jiph.2014.08.003","article-title":"Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV\/AIDS: A systematic review","volume":"8","author":"Cobucci","year":"2015","journal-title":"J. Infect. Public Health"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ajog.2015.03.034","article-title":"Prevalence of anal human papillomavirus infection and anal HPV-related disorders in women: A systematic review","volume":"213","author":"Stier","year":"2015","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.annonc.2021.06.015","article-title":"Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606","volume":"32","author":"Rao","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_22","unstructured":"Ahmed, A., Arbor, T.C., and Qureshi, W.A. (2022, December 05). Anatomy, Abdomen and Pelvis, Anal Canal, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554531\/."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-0029-1223845","article-title":"Malignancies of the anal margin and perianal skin","volume":"22","author":"Wietfeldt","year":"2009","journal-title":"Clin. Colon. Rectal. Surg."},{"key":"ref_24","unstructured":"(2019). WHO Classification of Tumours: Digestive System Tumours, International Agency for Research on Cancer. [5th ed.]."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/01.pas.0000213362.10756.d3","article-title":"Immunohistochemical staining for p63 is useful in the diagnosis of anal squamous cell carcinomas","volume":"31","author":"Owens","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/1541-7786.MCR-17-0060","article-title":"Comprehensive genomic profiling of metastatic squamous cell carcinoma of the anal canal","volume":"15","author":"Morris","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/annonc\/mdw152","article-title":"Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes","volume":"27","author":"Chung","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/s41379-020-00729-y","article-title":"Molecular and immunophenotypic characterization of anal squamous cell carcinoma reveals distinct clinicopathologic groups associated with HPV and TP53 mutation status","volume":"34","author":"Zhu","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/bjc.2015.20","article-title":"HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53","volume":"112","author":"Meulendijks","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1200\/OP.20.00363","article-title":"Anal adenocarcinoma: A rare malignancy in need of multidisciplinary management","volume":"16","author":"Lukovic","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.6004\/jnccn.2019.7309","article-title":"Impact of surgical resection on survival outcomes after chemoradiotherapy in anal adenocarcinoma","volume":"17","author":"Li","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.soc.2016.07.002","article-title":"Diagnosis and diagnostic imaging of anal canal cancer","volume":"26","author":"Ciombor","year":"2017","journal-title":"Surg. Oncol. Clin. N Am."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3348\/kjr.2017.18.6.946","article-title":"Cancer of the anal canal: Diagnosis, staging and follow-up with MRI","volume":"18","author":"Durot","year":"2017","journal-title":"Korean J. Radiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00330-010-1980-7","article-title":"Anal carcinomas: The role of endoanal ultrasound and magnetic resonance imaging in staging, response evaluation and follow-up","volume":"21","author":"Parikh","year":"2011","journal-title":"Eur. Radiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s13244-012-0199-3","article-title":"MRI and CT of anal carcinoma: A pictorial review","volume":"4","author":"Tonolini","year":"2013","journal-title":"Insights Imaging"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13027-016-0100-y","article-title":"Radiological assessment of anal cancer: An overview and update","volume":"11","author":"Granata","year":"2016","journal-title":"Infect. Agent Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"20170370","DOI":"10.1259\/bjr.20170370","article-title":"PET imaging in anal canal cancer: A systematic review and meta-analysis","volume":"90","author":"Mahmud","year":"2017","journal-title":"Br. J. Radiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Amin, M.B., Edge, S.B., Greene, F.L., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., and Sullivan, D.C. (2017). American Joint Committee on Cancer Staging Manual, Springer. [8th ed.].","DOI":"10.1007\/978-3-319-40618-3"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(17)30456-4","article-title":"Nodal stage migration and prognosis in anal cancer: A systematic review, meta-regression, and simulation study","volume":"18","author":"Sekhar","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1055\/s-2007-984865","article-title":"Abdominoperineal resection: How is it done and what are the results?","volume":"20","author":"Perry","year":"2007","journal-title":"Clin. Colon Rectal. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/1097-0142(19840701)54:1<114::AID-CNCR2820540124>3.0.CO;2-P","article-title":"Carcinoma of the anal canal. A clinical and pathologic study of 188 cases","volume":"54","author":"Boman","year":"1984","journal-title":"Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/1097-0142(19830401)51:7<1291::AID-CNCR2820510719>3.0.CO;2-R","article-title":"Depth of invasion, location, and size of cancer of the anus dictate operative treatment","volume":"51","author":"Schraut","year":"1983","journal-title":"Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF02586980","article-title":"Combined therapy for cancer of the anal canal: A preliminary report","volume":"17","author":"Nigro","year":"1974","journal-title":"Dis. Colon. Rectum."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0002-9343(85)90428-0","article-title":"Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy","volume":"78","author":"Leichman","year":"1985","journal-title":"Am. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.1996.14.12.3121","article-title":"Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: Results in 35 consecutive patients","volume":"14","author":"Doci","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/1097-0142(19951115)76:10<1731::AID-CNCR2820761009>3.0.CO;2-H","article-title":"Results of combined modality therapy for patients with anal cancer (E7283). An Eastern cooperative oncology group study","volume":"76","author":"Martenson","year":"1995","journal-title":"Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1023\/A:1008295119573","article-title":"Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: A French cooperative study","volume":"8","author":"Peiffert","year":"1997","journal-title":"Ann Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"UKCCCR Anal Cancer Trial Working Party (1996). Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UK Co-ordinating Committee on Cancer Research. Lancet, 348, 1049\u20131054.","DOI":"10.1016\/S0140-6736(96)03409-5"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","article-title":"Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups","volume":"15","author":"Bartelink","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: Survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): A randomised, phase 3, open-label, 2 \u00d7 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: Final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"abstr 4030","DOI":"10.1200\/jco.2012.30.15_suppl.4030","article-title":"Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5fluorouracil (5FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIVpositive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results","volume":"30","author":"Garg","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2016.69.1642","article-title":"Cetuximab plus chemoradiotherapy for HIV-associated anal carcinoma: A phase II AIDS malignancy consortium trial","volume":"35","author":"Sparano","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3109\/0284186X.2013.770599","article-title":"Impaired health-related quality of life after chemoradiotherapy for anal cancer: Late effects in a national cohort of 128 survivors","volume":"52","author":"Bentzen","year":"2013","journal-title":"Acta Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejon.2015.02.007","article-title":"Late effects and quality of life after chemo-radiation for the treatment of anal cancer","volume":"19","author":"Knowles","year":"2015","journal-title":"Eur. J. Oncol. Nurs."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: A phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijrobp.2021.08.008","article-title":"Long-term outcomes of NRG Oncology\/RTOG 0529: A phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in anal canal cancer","volume":"112","author":"Kachnic","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijrobp.2007.12.012","article-title":"EXTRA\u2014A multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer","volume":"72","author":"Meadows","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/bjc.2014.467","article-title":"Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: An alternative treatment option","volume":"111","author":"Meulendijks","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.soc.2016.07.007","article-title":"Surveillance of anal canal cancers","volume":"26","author":"Adams","year":"2017","journal-title":"Surg. Oncol. Clin. North Am."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1200\/JCO.2019.37.15_suppl.3571","article-title":"Outcomes of salvage surgery for anal squamous cell carcinoma: A systematic review and meta-analysis","volume":"37","author":"Cyr","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_65","first-page":"89","article-title":"Perineal colostomy: Advantages and disadvantages","volume":"17","author":"Mulita","year":"2022","journal-title":"Przegl\u0105d Gastroenterol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"171","DOI":"10.21037\/jgo.2018.12.12","article-title":"Local excision for patients with stage I anal canal squamous cell carcinoma can be curative","volume":"10","author":"Chakrabarti","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/jamasurg.2017.3151","article-title":"Management of stage I squamous cell carcinoma of the anal canal","volume":"153","author":"Chai","year":"2018","journal-title":"JAMA Surg."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ejso.2016.02.253","article-title":"Surgical excision alone for stage T1 anal verge cancers in people living with HIV","volume":"42","author":"Nelson","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s00384-020-03687-8","article-title":"Outcome following local excision of T1 anal cancers-a systematic review","volume":"35","author":"Pedersen","year":"2020","journal-title":"Int. J. Colorectal. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1080\/0284186X.2018.1442931","article-title":"Primary surgery with or without postoperative radiotherapy in early stage squamous cell carcinoma in the anal canal and anal margin","volume":"57","author":"Leon","year":"2018","journal-title":"Acta Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1200\/JCO.2007.14.2810","article-title":"Human immunodeficiency virus-associated squamous cell cancer of the anus: Epidemiology and outcomes in the highly active antiretroviral therapy era","volume":"26","author":"Chiao","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.radonc.2010.11.011","article-title":"Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: Are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy?","volume":"98","author":"Fraunholz","year":"2011","journal-title":"Radiother. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1200\/JCO.2007.15.2348","article-title":"HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: A multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy","volume":"26","author":"Huguet","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijrobp.2008.10.046","article-title":"Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients","volume":"75","author":"Seo","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/COC.0000000000000172","article-title":"Comparison of toxicity and treatment outcomes in HIV-positive versus HIV-negative patients with squamous cell carcinoma of the anal canal","volume":"40","author":"White","year":"2017","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijrobp.2006.03.049","article-title":"Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: Outcomes and toxicities","volume":"66","author":"Edelman","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ijrobp.2008.11.021","article-title":"Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement","volume":"75","author":"Hodges","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijrobp.2018.04.076","article-title":"Extended-field chemoradiation therapy for definitive treatment of anal canal squamous cell carcinoma involving the para-aortic lymph nodes","volume":"102","author":"Holliday","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"100180","DOI":"10.1016\/j.esmoop.2021.100180","article-title":"Squamous rectal carcinoma: A rare malignancy, literature review and management recommendations","volume":"6","author":"Astaras","year":"2021","journal-title":"ESMO Open"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.annonc.2020.06.012","article-title":"Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: Results of a post hoc analysis from the randomised phase III ACT II trial","volume":"31","author":"Meadows","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1158\/1078-0432.CCR-18-0922","article-title":"Prognostic impact of residual HPV ctDNA detection after chemoradiotherapy for anal squamous cell carcinoma","volume":"24","author":"Cabel","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3322\/caac.21712","article-title":"Current treatment and future directions in the management of anal cancer","volume":"72","author":"Tchelebi","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"11133","DOI":"10.18632\/oncotarget.2563","article-title":"The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal","volume":"5","author":"Eng","year":"2014","journal-title":"Oncotarget"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1634\/theoncologist.2016-0241","article-title":"Platinum-fluoropyrimidine and paclitaxel-based chemotherapy in the treatment of advanced anal cancer patients","volume":"22","author":"Sclafani","year":"2017","journal-title":"Oncologist"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct","volume":"38","author":"Rao","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(18)30321-8","article-title":"Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): A multicentre, single-arm, phase 2 study","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1158\/1078-0432.CCR-18-2984","article-title":"Clinical validity of HPV circulating tumor DNA in advanced anal carcinoma: An ancillary study to the epitopes-HPV02 trial","volume":"25","author":"Jeannot","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S2468-1253(21)00382-4","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study","volume":"7","author":"Marabelle","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): A multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1200\/JCO.2022.40.16_suppl.3508","article-title":"Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma: A SCARCE-PRODIGE 60 randomized phase II study (abstract)","volume":"40","author":"Kim","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2147\/JEP.S262342","article-title":"Emerging and experimental agents for anal cancer: What is new?","volume":"13","author":"Farias","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e002996","DOI":"10.1136\/jitc-2021-002996","article-title":"Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: The CARACAS study","volume":"9","author":"Lonardi","year":"2021","journal-title":"J. Immunother. Cancer."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1016\/j.annonc.2020.08.514","article-title":"Atezolizumab in combination with bevacizumab for patients with unresectable\/metastatic anal cancer","volume":"31","author":"Morris","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/DCR.0000000000000827","article-title":"Multimodal therapy of squamous cell carcinoma of the anus with distant metastasis: A single-institution experience","volume":"60","author":"Evesque","year":"2017","journal-title":"Dis. Colon. Rectum."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.amjsurg.2020.08.016","article-title":"Role of metastasectomy for liver metastasis in stage IV anal cancer","volume":"221","author":"Goldner","year":"2021","journal-title":"Am. J. Surg."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(17)30071-2","article-title":"ACT II study group. Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): A post-hoc analysis of randomised controlled phase 3 trial","volume":"18","author":"Meadows","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.radonc.2014.04.013","article-title":"Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"111","author":"Nilsson","year":"2014","journal-title":"Radiother. Oncol."},{"key":"ref_100","unstructured":"NCCN Clinical Practice Guideline in Oncology (2022, December 12). Anal Carcinoma. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/anal.pdf."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Savoie, M.B., Laffan, A., Brickman, C., Daniels, B., Levin, A., Rowen, T., Smith, J., Van Blarigan, E.L., Hope, T.A., and Berry-Lawhorn, J.M. (2019). A multi-disciplinary model of survivorship care following definitive chemoradiation for anal cancer. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6053-y"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1200\/EDBK_323525","article-title":"Management of long-term toxicity from pelvic radiation therapy","volume":"41","author":"Dalsania","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_103","first-page":"537","article-title":"Anorectal human papillomavirus: Current concepts","volume":"87","author":"Assi","year":"2014","journal-title":"Yale J. Biol. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4137\/CMO.S13241","article-title":"Human papilloma virus and squamous cell carcinoma of the anus","volume":"8","author":"Gami","year":"2014","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"698","DOI":"10.15585\/mmwr.mm6832a3","article-title":"Human papillomavirus vaccination for adults: Updated recommendations of the advisory committee on immunization practices","volume":"68","author":"Meites","year":"2019","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1473-3099(21)00327-3","article-title":"Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: Results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Goldstone","year":"2022","journal-title":"Lancet Infect Dis."},{"key":"ref_108","first-page":"CD013479","article-title":"Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males","volume":"2019","author":"Bergman","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1056\/NEJMoa2201048","article-title":"Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer","volume":"386","author":"Palefsky","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_110","unstructured":"Hirsch, B.E., McGowan, J.P., Fine, S.M., Vail, R., Merrick, S.T., Radix, A., Hoffmann, C.J., and Gonzalez, C.J. (2022, December 25). Screening for Anal Dysplasia and Cancer in Adults with HIV. Baltimore, M.D., Johns Hopkins University, 2022, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556472\/."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/3\/246\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:52:39Z","timestamp":1760122359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/3\/246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":110,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["curroncol30030246"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30030246","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,11]]}}}